Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 24
- Registration Number
- NCT06743581
- Locations
- 🇨🇦
Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT06705387
- Locations
- 🇺🇸
Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, Colorado, United States
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06695897
- Locations
- 🇩🇪
Investigational Site Number: 0000001, Dachau, Bayern, Germany
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06693531
- Locations
- 🇺🇸
Boston Specialists, Boston, Massachusetts, United States
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT06687980
- Locations
- 🇺🇸
Austin Institute for Clinical Research - Pflugerville- Site Number : 8400203, Pflugerville, Texas, United States
🇺🇸Progressive Clinical Research - San Antonio- Site Number : 8400206, San Antonio, Texas, United States
🇨🇦Investigational Site Number : 1240205, London, Ontario, Canada
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT06687967
- Locations
- 🇨🇦
Investigational Site Number : 1240001, London, Ontario, Canada
🇨🇦Investigational Site Number : 1240002, Saskatoon, Saskatchewan, Canada
🇯🇵Investigational Site Number : 3920003, Tachikawa, Tokyo, Japan
Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
- Conditions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 300
- Registration Number
- NCT06683261
- Locations
- 🇧🇪
Onze Lieve Vrouw hospital Aalst, Aalst, Belgium
🇧🇪General hospital Sint-Jan Bruges, Bruges, Belgium
🇧🇪University hospital Saint-Luc, Bruxelles, Belgium
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Rima Patel
- Target Recruit Count
- 15
- Registration Number
- NCT06637306
- Locations
- 🇺🇸
Mount Sinai Health System, New York, New York, United States
Compassionate Use of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
- Conditions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06631677
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT06572228
- Locations
- 🇺🇸
Henderson Clinical Trials, Henderson, Nevada, United States
🇺🇸Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States
🇺🇸Clinical Research Associates of Central PA, DuBois, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.